Lenalidomide 20 mg

DRUG3 trials

Conditions

ChemotherapyDiffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL), NosElderlyFollicular LymphomaHodgkin LymphomaMultiple MyelomaMyelodysplastic Syndrome

Phase 1

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

CompletedNCT01953692

Merck Sharp & Dohme LLCDiffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma +4

Start: 2013-11-22End: 2020-06-26Updated: 2021-08-04

Phase 2

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

CompletedNCT04113226

Centre Hospitalier Universitaire, AmiensChemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly

Start: 2021-11-09End: 2024-06-04Updated: 2026-06-12

Phase 3

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Not yet recruitingNCT07355283

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Relapsed/Refractory Follicular Lymphoma

Start: 2026-02-01End: 2030-10-01Target: 198Updated: 2026-01-27

Blood2023-05-0256 citations

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes.

2023-03-019 citations

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

Leukemia & lymphoma/Leukemia and lymphoma2022-11-1826 citations

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

HemaSphere2022-06-01

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Leukemia & lymphoma/Leukemia and lymphoma2022-03-0418 citations

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Blood2021-11-05

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood2020-09-0156 citations

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Blood Advances2020-06-1751 citations

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Journal of Clinical Oncology2019-10-14255 citations

Relevant Biomarkers for the Treatment of Hematological Malignancies

Oncology Times2019-08-28

Immunogenicity of pembrolizumab in patients with advanced tumors

Journal for ImmunoTherapy of Cancer2019-08-0853 citations

PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP

Hematological Oncology2019-06-01

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: <scp>KEYNOTE</scp>‐013

British Journal of Haematology2019-04-0181 citations

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood2018-11-2922 citations

PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL

Hematological Oncology2017-06-017 citations

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Blood2017-05-11294 citations

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Blood2016-12-0257 citations

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Blood2016-12-0232 citations

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Blood2016-12-0212 citations

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Journal of Clinical Oncology2016-06-29668 citations

4 more papers not shown

Lenalidomide 20 mg

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers